335 results on '"Scaltriti, M"'
Search Results
2. Overview of the relevance of PI3K pathway in HR-positive breast cancer
3. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research
4. Present and future breast cancer management—bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry
5. List of Contributors
6. Methodologies for Developing and Maintaining Patient-Derived Xenograft Mouse Models
7. Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells
8. BLOCKING PD-1/PD-L1 AXIS IS REQUIRED FOR PROLONGED RESPONSE TO TRAMETINIB IN TONGUE AND LIP CANCER MODELS IN MICE
9. 2341P Novel therapeutic opportunities in metaplastic breast cancer
10. Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status
11. Cyclin E amplification/overexpression is associated with poor prognosis in gastric cancer
12. Solti-1903 hope: Real-world clinical practice study to assess the impact of using comprehensive genomic data on the next treatment decision making-choice in patients with locally advanced or metastatic breast cancer in Spain
13. Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers
14. Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth
15. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity
16. FP14.15 Neratinib-Based Combination Therapy in HER2-Mutant Lung Adenocarcinomas: Findings from two International Phase 2 Studies
17. TransFAL: Establishment of clinical trial-matched luminal breast cancer patient-derived xenografts (PDX) for translational studies
18. Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer
19. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
20. 1933MO TransFAL: Establishment of clinical trial-matched luminal breast cancer patient-derived xenografts (PDX) for translational studies
21. 1954P A pan-cancer analysis of double PIK3CA mutations
22. Corrigendum to Overview of the relevance of PI3K pathway in HR-positive breast cancer
23. Characterization of the mechanism of action and efficacy of MEN1611 (PA799), a novel PI3K inhibitor, in breast cancer preclinical models
24. Inhibition of Spontaneous and Androgen-Induced Prostate Growth by a Nonhypercalcemic Calcitriol Analog
25. Nuclear Translocation of a Clusterin Isoform Is Associated with Induction of Anoikis in SV40-Immortalized Human Prostate Epithelial Cells
26. Somatic PIK3CA mutations as a driver of sporadic venous malformations (vol 10, eaav7520, 2018)
27. Double PIK3CA mutations in cis enhance PI3Kα oncogene activation and sensitivity to PI3Kα inhibitors in breast cancer
28. Abstract P6-18-02: Primary and secondary results of the first nationwide molecular screening program in Spain for patients with advanced breast cancer (AGATA SOLTI-1301 study)
29. P1.13-43 Molecular and Imaging Predictors of Response to Ado-Trastuzumab Emtansine in Patients with HER2 Mutant Lung Cancers: An Exploratory Phase 2 Trial
30. Primary results of the first nationwide molecular screening program in Spain for patients with advanced breast cancer (AGATA SOLTI-1301 study)
31. Chapter 3 - Methodologies for Developing and Maintaining Patient-Derived Xenograft Mouse Models
32. Tumor-infiltrating lymphocytes density correlates with HER2 gene copy number but not with protein levels in HER2-positive breast cancer
33. Why is PI3K so hard?
34. Abstract P2-09-29: Potential recurrence markers of locally advanced triple negative breast cancer treated by combined neoadjuvant EGFR targeting and chemotherapy, revealed by genomic analyses and assessment of tumor-infiltrating lymphocytes
35. Abstract P5-21-32: AZD5363 in combination with fulvestrant in AKT1-mutant ER-positive metastatic breast cancer
36. Abstract P5-21-05: Withdrawn
37. OA 14.05 Phase 2 Basket Trial of Ado-Trastuzumab Emtansine in Patients with HER2 Mutant or Amplified Lung Cancers
38. Somatic PIK3CA mutations as a driver of sporadic venous malformations
39. 1938P - Characterization of the mechanism of action and efficacy of MEN1611 (PA799), a novel PI3K inhibitor, in breast cancer preclinical models
40. Genomic analyses reveal potential recurrence markers of locally advanced triple negative breast cancer treated by combined neoadjuvant EGFR targeting and chemotherapy
41. AGATA molecular screening program: Implementing precision medicine in patients with advanced breast cancer in Spain
42. Tumor-specific PI3K inhibition by targeted delivery in head and neck squamous cell carcinoma
43. Neratinib induces estrogen receptor function and sensitizes HER2-mutant breast cancer to anti-endocrine therapy
44. Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
45. Molecular characterization of HER2-positive (HER2+) metastatic gastric and gastro-esophageal junction cancer patients (mGC): Identification of resistance mechanisms to trastuzumab-based therapy (TTZ)
46. 284O - Primary results of the first nationwide molecular screening program in Spain for patients with advanced breast cancer (AGATA SOLTI-1301 study)
47. Targeting HER2 and PI3K in Uterine Serous Cancer
48. Un nuovo autunno caldo nel Mezzogiorno? Note in margine al dibattito sui differenziali salariali territoriali
49. 440 (PB-073) - Tumor-infiltrating lymphocytes density correlates with HER2 gene copy number but not with protein levels in HER2-positive breast cancer
50. 30IN - Why is PI3K so hard?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.